IBSA Group is firmly committed to developing effective therapies for the treatment of disorders and diseases with a high social impact in terms of both costs and quality of life. Its history has been characterised by the courage and outlook of its Founder, Arturo Licenziati, since he purchased IBSA (Institut Biochimique SA), a small Swiss pharmaceutical company based in Lugano, in 1985.
Within just a few years, IBSA’s shrewd strategy based on constant improvements in the quality, effectiveness and convenience of the new products developed by its researchers, had led to rapid expansion: new manufacturing sites were built in Lugano and branch offices were established in France and Italy, followed by a number of other international markets.
True to his pioneering spirit and propensity for innovation, the ingenuity of Founder and CEO, Arturo Licenziati, has allowed IBSA Group to invest with success, earlier and better than others, in therapeutic areas and in products on which few would have wagered. The strategic factors, thanks to which IBSA is able to consolidate its position with such innovative products, in therapeutic areas undergoing constant evolution, and in markets as diverse as the US and European ones, include creativity and the constant ability to play as a team in order to develop novel and challenging products, with dozens of patents already developed and still more in the pipeline.
“One of the keys to its success lies in IBSA’s rare ability to fully exploit the innovation potential and excellence of its industrial partners”, explains Franco Daglio, Chief of Technical Operations & Technical Director IBSA Group, “in an on-going quest for the most effective synergies, thanks to the special business and personal relationships it has forged over the years with its suppliers, based on mutual trust and commitment”.